Risk of Malignancy and Biologic Therapy in Rheumatic Inflammatory Diseases: A Single-center Experience

OBJECTIVES: Biologic disease modifying anti-rheumatic drugs (bDMARDs) have significantly improved the care of patients with rheumatic muscle-skeletal disorders (RMDs). Considering their immunosuppressive action, a theoretical increase of malignancy risk has been a major concern in the last few decad...

Descripción completa

Detalles Bibliográficos
Autores principales: Cometi, Laura, Bruni, Cosimo, Passavanti, Saverio, Tofani, Lorenzo, Bartoli, Francesca, Fiori, Ginevra, Nacci, Francesca, Lepri, Gemma, Orlandi, Martina, Melchiorre, Daniela, Antonuzzo, Lorenzo, Matucci-Cerinic, Marco, Moggi-Pignone, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524767/
https://www.ncbi.nlm.nih.gov/pubmed/36465081
http://dx.doi.org/10.2478/rir-2020-0001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524767/
https://www.ncbi.nlm.nih.gov/pubmed/36465081
http://dx.doi.org/10.2478/rir-2020-0001

Ejemplares similares